[{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hypera Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0.82999999999999996,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.82999999999999996,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Hypera Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Hypera Pharma"},{"orgOrder":0,"company":"Galt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Orphenadrine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Galt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galt Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"DSE Healthcare Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"DSE Healthcare Solutions","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"DSE Healthcare Solutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"DSE Healthcare Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Butalbital","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hypera Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Small molecule","year":"2021","type":"Divestment","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0.82999999999999996,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.82999999999999996,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Hypera Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Hypera Pharma"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Seton Pharmaceuticals","sponsor":"Senores Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Butalbital","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Seton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seton Pharmaceuticals \/ Senores Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Seton Pharmaceuticals \/ Senores Pharmaceuticals"},{"orgOrder":0,"company":"Comera Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"CTLA-4","graph1":"Oncology","graph2":"Preclinical","graph3":"Comera Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Comera Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Comera Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"SkinMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Coffea Arabica","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"SkinMedica","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"SkinMedica \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SkinMedica \/ Not Applicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Coffea Arabica","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Allergan Aesthetics \/ Not Applicable"},{"orgOrder":0,"company":"Comera Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Caffeine","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Comera Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Comera Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Comera Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Famar","sponsor":"LaviPharm","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GREECE","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Paracetamol","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Famar","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Famar \/ LaviPharm","highestDevelopmentStatusID":"12","companyTruncated":"Famar \/ LaviPharm"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Butalbital","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Butalbital","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Nura Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Series A Financing","leadProduct":"NB-4746","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Nura Bio","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Nura Bio \/ The Column Group","highestDevelopmentStatusID":"6","companyTruncated":"Nura Bio \/ The Column Group"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"LaviPharm","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Paracetamol","moa":"||COX1\/2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Lavipharm","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Lavipharm"}]

Find Clinical Drug Pipeline Developments & Deals for CAFERGOT

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Lead Product(s) : Paracetamol,Caffeine,Codeine Phosphate

Therapeutic Area : Immunology

Study Phase : Approved

Sponsor : LaviPharm

Deal Size : Undisclosed

Deal Type : Collaboration

Details : Under the collaboration, FAMAR will produce two analgesic pharmaceutical products for Lavipharm: Lonarid N (paracetamol) and Lonalgal (caffeine anhydrous).

Product Name : Lonarid N

Product Type : Small molecule

Upfront Cash : Undisclosed

January 23, 2024

Lead Product(s) : Paracetamol,Caffeine,Codeine Phosphate

Therapeutic Area : Immunology

Highest Development Status : Approved

Sponsor : LaviPharm

Deal Size : Undisclosed

Deal Type : Collaboration

Famar

02

Details : The SkinMedica (coffea arabica) Even & Correct products are hydroquinone-free, well tolerated, and effective on all skin types and for multiple ethnicities. Most SkinMedica® products are intended to meet the FDA's definition of a cosmetic product.

Product Name : SkinMedica

Product Type : Small molecule

Upfront Cash : Not Applicable

January 17, 2023

Lead Product(s) : Coffea Arabica,Caffeine,Hydrolyzed Rice Protein

Therapeutic Area : Dermatology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Abbvie CB

03

Lead Product(s) : Paracetamol,Aspirin,Caffeine

Therapeutic Area : Neurology

Study Phase : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : The US Food & Drug Administration (US FDA) has approved Abbreviated New Drug Application (ANDA) for Acetaminophen, Aspirin and Caffeine Tablets USP, 250 mg/250 mg/65 mg (OTC).

Product Name : Acetaminophen/Aspirin/Caffeine-Generic

Product Type : Small molecule

Upfront Cash : Not Applicable

February 24, 2021

Lead Product(s) : Paracetamol,Aspirin,Caffeine

Therapeutic Area : Neurology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Granules India

04

Lead Product(s) : Butalbital,Paracetamol,Caffeine

Therapeutic Area : Neurology

Study Phase : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Strides Pharma has received approval for Butalbital, Acetaminophen, and Caffeine Tablets USP, 50 mg/325 mg/40 mg from the U.S Food & Drug Administration. The product is indicated for the relief of the symptom complex of tension (or muscle contraction) he...

Product Name : Undisclosed

Product Type : Small molecule

Upfront Cash : Not Applicable

September 22, 2020

Lead Product(s) : Butalbital,Paracetamol,Caffeine

Therapeutic Area : Neurology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Strides Pharma Science

05

Lead Product(s) : Butalbital,Paracetamol,Caffeine

Therapeutic Area : Neurology

Study Phase : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : USFDA approved generic version of Butalbital, Acetaminophen, Caffeine with Codeine Phosphate Capsules which is indicated for the relief of the symptom complex of tension headache (migraine).

Product Name : Fioricet-Generic

Product Type : Small molecule

Upfront Cash : Not Applicable

July 09, 2020

Lead Product(s) : Butalbital,Paracetamol,Caffeine

Therapeutic Area : Neurology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Strides Pharma Science

06

Lead Product(s) : Butalbital,Paracetamol,Caffeine

Therapeutic Area : Neurology

Study Phase : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : USFDA approved generic version of Butalbital, Acetaminophen, Caffeine Capsules which is indicated for the relief of the symptom complex of tension headache (migraine).

Product Name : Butalbital-Generic

Product Type : Small molecule

Upfront Cash : Not Applicable

April 09, 2020

Lead Product(s) : Butalbital,Paracetamol,Caffeine

Therapeutic Area : Neurology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Granules India

07

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : The financing will support the clinical development of NB-4746, a SARM1 inhibitor currently being evaluated in early-stage trials for the treatment of amyotrophic lateral sclerosis.

Product Name : NB-4746

Product Type : Small molecule

Upfront Cash : Undisclosed

September 17, 2024

Lead Product(s) : NB-4746,Caffeine,Midazolam

Therapeutic Area : Neurology

Highest Development Status : Phase I

Sponsor : The Column Group

Deal Size : $140.0 million

Deal Type : Series A Financing

blank

08

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : Company acquires two analgesic pharmaceutical products, Lonarid N® and Lonalgal®, used for fever and pain, for Greece and Cyprus markets with the intention to commercialize them internationally.

Product Name : Lonarid N

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

December 01, 2023

Lead Product(s) : Paracetamol,Caffeine,Codeine Phosphate

Therapeutic Area : Immunology

Highest Development Status : Approved FDF

Sponsor : LaviPharm

Deal Size : Undisclosed

Deal Type : Acquisition

blank

09

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : SkinMedica® Firm & Tone Lotion for Body is a luxurious formula rooted in science that delivers transformative results. It is clinically proven to diminish the look of crepey skin, address uneven skin texture, improve the appearance of skin and tone, and...

Product Name : SkinMedica

Product Type : Small molecule

Upfront Cash : Not Applicable

August 31, 2022

Lead Product(s) : Coffea Arabica,Caffeine,Hydrolyzed Rice Protein

Therapeutic Area : Dermatology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

10

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : Comera announced favorable topline results of its SEQURUS-1 preclinical study in July, demonstrating supportive evidence of the safety of Comera’s lead caffeine-based proprietary SQore excipient when administered as a SQ biologic drug product formulati...

Product Name : Undisclosed

Product Type : Large molecule

Upfront Cash : Not Applicable

August 11, 2022

Lead Product(s) : Ipilimumab,Caffeine

Therapeutic Area : Oncology

Highest Development Status : Preclinical

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank